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Psychostimulants such as methamphetamine (MA) induce significant alterations in the
function of the hypothalamic-pituitary-adrenal (HPA) axis. These changes in HPA axis
function are associated with altered stress-related behaviors and might contribute to
addictive processes such as relapse. In this mini-review we discuss acute and chronic
effects of MA (adult and developmental exposure) on the HPA axis, including effects on
HPA axis associated genes/proteins, brain regions, and behaviors such as anxiety and
depression. A better understanding of the mechanisms through which MA affects the
HPA axis may lead to more effective treatment strategies for MA addiction.
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Introduction
Abuse of amphetamine-like substances, including methamphetamine (MA), ranks second to
cannabis in terms of worldwide illicit drug use (UNODC, 2011). A 2012 report indicates that in the
United States MA is abused by approximately 439,000 people (SAMHSA, 2012), costing the United
States approximately $23.4 billion annually (Nicosia et al., 2009). MA abuse is associated with high
rates of relapse. A recent study indicated that 61% of MA users relapse to MA abuse within a
year of release from treatment programs (Brecht and Herbeck, 2014). Furthermore, only 13% of
individuals maintained abstinence from MA over the 5 year duration of the study (Brecht and
Herbeck, 2014). Despite widespread need for improved MA addiction treatment options, current
psychological and particularly pharmacological treatments for MA abuse have had limited success
(Carson and Taylor, 2014).
Stress and the hypothalamic-pituitary-adrenal (HPA) axis are key components in
psychostimulant addiction. Repeated drug use can induce functional and morphological changes
in the HPA axis including alterations in stress hormone release as well as genes and proteins
[e.g., corticotropin-releasing factor (CRF), arginine vasopressin (AVP), and glucocorticoid
receptor (GR)] within brain regions pertinent to HPA axis function [e.g., extended amygdala,
paraventricular hypothalamus (PVN); (Mantsch et al., 2007; Nawata et al., 2012)]. These changes
contribute to a shift to the anti-reward pathway of drug abuse which is hypothesized to be activated
secondarily to the reward pathway. This involves a change in the motivation from abusing drugs
for their “pleasurable” effects to a desire to reduce internal distress (Koob et al., 2014). Emerging
studies in humans indicate that the HPA axis is altered by repeated MA use, with individuals
showing altered levels of stress hormones during withdrawal (Carson et al., 2012; Li et al., 2013).
These alterations may contribute to adverse effects of MA, such as depression and anxiety, which
in turn perpetuate further MA use. In this mini-review we summarize existing literature related to
MA effects on the HPA axis and associated stress-related behaviors.
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MA Activates the HPA Axis
Numerous studies have demonstrated that MA activates the HPA
axis (Morimasa et al., 1987; Williams et al., 2000; Zuloaga et al.,
2014). Similar to stress- induced activation of the HPA axis,
increased production of adrenocorticotropic hormone (ACTH)
secretagogues (CRF and AVP) in neurons of the PVN is essential.
When stimulated, AVP-expressing cells of the parvocellular
PVN act in conjunction with CRF-expressing cells to activate
cells in the anterior pituitary gland. This, in turn, stimulates
cleavage of proopiomelanocortin (POMC) to produce ACTH in
corticotropic cells. ACTH then enters the systemic blood stream
and stimulates the adrenal cortex to release glucocorticoids
(e.g., corticosterone and cortisol). Glucocorticoids circulate
throughout the body and exert effects on numerous organs
including the brain. This response is terminated through
activation of GRs in the brain and pituitary which, via negative
feedback, decrease further release of CRF and ACTH.
Activation of the HPA is an adaptive response which
prepares an organism for “fight or flight” associated situations.
However, in instances of chronic activation of the HPA axis
(e.g., glucocorticoid treatments, chronic stress, or abuse of
certain illicit drugs) glucocorticoids can be harmful. Excessive
glucocorticoid exposure can exert negative effects on the brain
including: increasing cell death (Zuloaga et al., 2011), altering
cell proliferation patterns (Kim et al., 2004), and inducing
dendritic remodeling (Kim et al., 2014). Repeated exposure
to elevated glucocorticoids can also alter brain expression of
genes and proteins associated with the HPA axis including CRF,
AVP, GR, and mineralocorticoid receptor (MR; Imaki et al.,
1991; Reul et al., 1987; Herman et al., 1989; Sawchenko et al.,
1993). These alterations contribute to lasting effects on HPA
axis function. Disrupted HPA axis function, including altered
glucocorticoid release, are hallmarks of depressive and anxiety
spectrum disorders in humans as well as related symptomology
in rodents (Carroll et al., 1968; Landgraf et al., 1999). These
affective mood states have been linked to both the onset of
drug use as well as relapse (Haass-Koﬄer et al., 2014). See
Figure 1 for a hypothetical mechanism through which MA use,
via hyper-activation of the HPA axis, may induce changes in HPA
axis associated genes/proteins within pertinent brain regions.
Disruptions in the HPA axis and related behaviors such as anxiety
and depressionmay potentially contribute to subsequentMAuse.
MA administration, ranging from 1 to 40mg/kg, induces
robust increases in corticosterone in rodents (Herring et al.,
2008a; Zuloaga et al., 2014) and cortisol in nonhuman primates
(Madden et al., 2005). A study in humans also reported
elevated plasma cortisol in MA users that were intravenously
administered a 0.5mg/kg dose of MA (Harris et al., 2003). Recent
studies in humans also indicate that chronic MA abuse can
alter HPA axis function (Carson et al., 2012; Li et al., 2013).
MA-dependent individuals show elevated ACTH and decreased
cortisol levels at 96 h of MA abstinence compared to matched
controls Li et al., 2013. These same MA-dependent individuals
displayed elevated depressive symptomology (Li et al., 2013),
indicating that both the HPA axis and associated behaviors are
affected in recently abstinent MA abusers. Withdrawal from
MA is commonly associated with elevated states of anxiety and
depression (London et al., 2004; Cruickshank and Dyer, 2009),
although whether these mood states are directly linked to altered
HPA axis function is unknown.
In rats, chronic MA self-administration also increases anxiety
and depressive-like behaviors during withdrawal from MA
(Nawata et al., 2012; Jang et al., 2013). A single high dose
injection of MA can also induce lasting depressive-like behavior
in mice (Silva et al., 2014). Studies investigating effects of adult
chronic MA on glucocorticoid release are few in number and
have yielded mixed results, which may depend on timing, dose
and method of administration. For example, Nawata et al. (2012)
reported no alterations in blood corticosterone levels at 10 days
of withdrawal from MA self-administration. However, other
studies have reported lasting effects of MA on glucocorticoid
levels. A neurotoxic dose of MA elevated basal corticosterone
levels compared to controls at 24 h, 72 h, and 47 days after
administration (Herring et al., 2008a,b; Grace et al., 2010b).
Furthermore, chronic MA administration in drinking water
alters the circadian rhythm of corticosterone 1 week post-
withdrawal (Morimasa et al., 1987). Further studies specifically
directed at investigating the HPA axis are needed to clarify the
role of chronic MA on subsequent glucocorticoid release.
Developmental MA Exposure
Because the rate of MA abuse is high in women of childbearing
age, there is increased interest in the developmental effects
on infants prenatally exposed to MA. However, there are few
investigations of either short- or long-term effects of early
developmental MA exposure, particularly in the context of
alterations in the HPA axis function. A 2-year follow up study
of children prenatally exposed to MA found that stress-induced
cortisol levels were significantly higher in MA-exposed infants
(Kirlic et al., 2013). Behavioral effects that may be associated with
HPA axis alterations in prenatal MA exposed human offspring
include altered arousal in infants (Smith et al., 2012; Kiblawi et al.,
2014) and increased emotional reactivity and anxiety/depressed
behavior in 3–5 year olds (LaGasse et al., 2012; Abar et al.,
2013). Polydrug abuse, domestic violence, and emotional neglect
are highly associated with parental MA abuse. These confounds
make it difficult to dissociate effects of MA from other variables,
necessitating use of animal models to explore specific effects
of MA.
Extensive brain, particularly hippocampal, development
occurs during the postnatal period in the rodent, while in
humans analogous development occurs prenatally (Workman
et al., 2013). Due to these differences in developmental trajectory,
themajority of studies involving developmentalMA and theHPA
axis in rodents have utilized neonatal administration. Similar
to adult MA exposure, neonatal administration also induces
robust elevations in blood corticosterone (Acevedo et al., 2008;
Grace et al., 2008). These elevations in corticosterone are greater
than those induced by severe psychological stressors such as
forced swim (Grace et al., 2008). An important consideration
in developmental MA models is the timing of treatment which
can cause differential effects on glucocorticoid release and
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FIGURE 1 | Proposed scenario for MA effects on the HPA axis and
behavior. MA activation of the HPA axis involves release of CRF from
neurosecretory cells of the paraventricular hypothalamic nucleus and
subsequent release of ACTH and glucocorticoids from the anterior pituitary
and adrenal cortex, respectively. Release of glucocorticoids is greater in
females than males. High levels of glucocorticoids may contribute to
alterations in HPA axis associated genes/proteins (CRF, AVP, GR). These
effects in the brain may subsequently alter HPA axis function (release of
stress hormones) and in turn affect anxiety- and depressive-related behaviors
often observed during withdrawal. Altered HPA axis function and mood
behaviors may provide bi-directional positive feedback, thereby exacerbating
these effects. Altered mood behaviors can lead to a need to alleviate an
aversive mood state, thereby increasing the risk of further MA use as a
means to reduce internal distress. The relationship between the elevated
glucocorticoid response to MA in females and brain and behavioral
consequences are currently unknown.
behavior (Williams et al., 2003; Schaefer et al., 2008). Specifically,
treatment that coincides with the neonatal stress hyporesponsive
period (SHRP), during which basal and stress/drug induced
glucocorticoid release are naturally blunted, results in the greatest
long-term deficits in learning and memory (Acevedo et al., 2007;
Vorhees et al., 2009).
Although long-term deficits on learning and memory
following neonatal MA exposure are well documented, lasting
effects on HPA axis function and stress-related behaviors are
more subtle and findings are mixed. MA exposure near the
neonatal SHRP results in subtle effects on adult HPA axis
responses, including a more rapid rise in plasma corticosterone
after forced swim (Grace et al., 2012). However, no long term
effects in plasma corticosterone were found in similarly exposed
rats following adult forced confinement or challenge with MA
(Grace et al., 2012). Prenatal MA exposure in rats failed to induce
any effects on adult basal plasma ACTH and corticosterone
levels (Cabrera et al., 1993). Furthermore, several reports indicate
that neonatal MA exposure does not alter anxiety-like behaviors
in adolescent or adult mice (Siegel et al., 2011; Eastwood
et al., 2012). However, in rats, several neonatal MA treatment
regimens result in subtle decreases in anxiety-like behaviors
in adulthood (Williams et al., 2003; Grace et al., 2010a). On
the contrary, postnatal MA exposure via breast milk induced
increased anxiety behavior in adult rats while prenatal MA
induced no behavior effects (Hruba et al., 2012). Little is known
about developmental effects of MA on depression-associated
behavior, although juvenile exposure increases adult depressive
behavior in mice (Joca et al., 2014). Together these findings
indicate that developmental effects on glucocorticoids and stress-
related behaviors are subtle and highly dependent on species
examined, dose, and timing of treatment.
HPA Axis Associated Neuropeptides and Neural
Receptors Associated with MA
Numerous studies indicate CRF regulates stress-related
behaviors. Administration of CRF and genetic overexpression
of CRF increase anxiety-related behaviors in rodents (Stenzel-
Poore et al., 1994; Spiga et al., 2006). Conversely, administration
of CRF antagonists has opposite effects, decreasing anxiety
behaviors (Rassnick et al., 1993). CRF and CRF receptors
(CRF-R1/CRF-R2) have also been implicated in MA abuse.
CRF mRNA is elevated in the nucleus accumbens following
injection with MA (Martin et al., 2012). Furthermore, exposure
to a high dose of MA (10mg/kg) enhances mRNA levels of
CRF to a subsequent lesser dose of MA (2.5mg/kg) in the rat
nucleus accumbens (Cadet et al., 2014). This indicates that
prior exposure to MA can induce greater elevations in CRF.
Interestingly, rats that had previously self-administered MA
showed elevated levels of CRF in the amygdala and plasma at 10
days of MA withdrawal (Nawata et al., 2012). These elevations in
CRF were associated with increased anxiety behaviors and stress-
induced reinstatement of MA-seeking (Nawata et al., 2012).
The non-selective CRF receptor antagonist (α-helical CRF9–41)
decreases MA-seeking behavior induced by stress (Nawata et al.,
2012). Furthermore, selective CRF-R1 antagonists attenuate both
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cue-and MA-induced reinstatement of MA-seeking (Moffett
and Goeders, 2007). These studies indicate that CRF antagonists
may be effective treatments for decreasing symptoms such as
anxiety, depression, and craving that are associated with MA
withdrawal. Recent evidence also indicates AVP as a potential
target for MA effects. Similar to CRF, prior exposure to MA can
elevate subsequent MA-induced AVP mRNA in the rat nucleus
accumbens (Cadet et al., 2014). Another study indicates that
antagonism of an AVP receptor subtype (AVPR1b) contributes to
MA-induced conditioned place preference (Subiah et al., 2012).
Developmental studies indicate AVP is particularly vulnerable
to MA. Exposure during neonatal and adolescent periods causes
lasting reductions in AVP-expressing cells in the PVN (Zuloaga
et al., 2013; Joca et al., 2014).
Other HPA axis associated proteins GR and MR are also
affected by MA administration. MA exposure decreases GR, and
to a lesser extent MR, in the hippocampus and hypothalamus
of rodents (Lowy, 1990; Lowy and Novotney, 1994; Kabbaj
et al., 2003). Within the PVN and central amygdala (CEA),
there is also a robust activation of glucocorticoid receptor (GR)
positive cells, identified by a significant increase in c-Fos/GR
dual-labeled cells, following MA treatment. This indicates MA
targets this cell phenotype in the brain and as a result may exert
lasting effects on the function of these neurons. Studies involving
pharmacological blockade of GR indicate that activation of
GR is involved in increasing locomotor activity following MA
treatment (Ago et al., 2009), although its role in other MA
processes such as MA-seeking and reinstatement is unknown.
See Table 1 for a summary of main findings regarding MA
effects on glucocorticoids, HPA axis associated genes/proteins,
and stress-related behaviors.
Blockade of MA-induced glucocorticoid synthesis using
metyrapone has been utilized to study the effects of
glucocorticoids on MA-associated behaviors, particularly in
the context of stress and cued reinstatement of MA use.
Metyrapone administration failed to block stress induced MA
seeking behavior in mice previously exposed to MA (Nawata
et al., 2012). However, a combined treatment of metyrapone with
the benzodiazepine oxazepam attenuated MA seeking induced
by the presentation of a conditioned reinforcer (Keller et al.,
2013), indicating at least some involvement of glucocorticoids in
this response. In cocaine models, metyrapone reduces cocaine-
induced locomotion and relapse of cocaine self-administration
(Piazza et al., 1994; Marinelli et al., 1997). Little is known
about corticosterone synthesis blockade on many MA-induced
behaviors as it has largely been studied in the context of
withdrawal.
Neuroanatomical Regions Associated with MA
and the HPA Axis
Psychostimulant effects on the HPA axis and the anti-reward
pathway of addiction are commonly associated with extended
amygdala circuitry (Koob and Volkow, 2010). However, studies
utilizing immediate early genes as markers of neural activation
have been useful in identifying other candidate regions involved
in MA regulation of the HPA axis. HPA axis associated
brain areas including hypothalamic, hippocampal, cortical, and
extended amygdala sub-regions show extensive immediate early
gene responses following MA administration (Giardino et al.,
2011; Tomita et al., 2013; Zuloaga et al., 2014). Even a relatively
low dose of MA (1mg/kg) induces a 4–5 fold increase in the
number of c-Fos positive cells within the PVN and CEA, two
regions central to regulation of the HPA axis. Less is known
about potential alterations in neural activation patterns in HPA
axis-associated brain regions following chronic MA exposure.
The majority of studies involving repeated psychostimulant
exposure on immediate early gene responses have focused on
the neostriatum and nucleus accumbens (McCoy et al., 2011).
In these regions, repeated MA blunts neural activation (McCoy
et al., 2011). Another study involving MA self-administration
reported that repeatedMA decreases c-Fos in the CEA and BNST
(Cornish et al., 2012). This finding indicates that neural activation
patterns in HPA axis associated brain regions are affected by
chronic MA exposure. Further understanding of the effects of
repeated MA use on neural activation within these and other
brain areas that regulate the HPA axis may reveal specific brain
circuits associated with MA addiction.
Sex Differences in MA Effects on the HPA Axis
MA activation of the HPA axis is sex- dependent in neonatal and
adult mice. In postnatal day 20 mice, MA induces a significant
increase in corticosterone in females but not males (Acevedo
et al., 2008). In adult mice, a 1mg/kg dose of MA induces
a protracted elevation in corticosterone in females compared
to males (Zuloaga et al., 2014). This sex difference may be
related to HPA axis negative feedback. Male mice display greater
numbers of c-Fos positive and dual-labeled c-Fos/GR positive
cells in two regions that regulate HPA axis negative feedback
(CA3 and cingulate cortex) following the same dose of MA.
Given the role of GR in regulating negative feedback (Sapolsky
et al., 1985), this indicates a potential mechanism through which
males confer a more rapid shutdown of the HPA axis than
females. Potential sex differences in the effects of repeated MA
exposure on HPA axis function are currently unknown but
are likely critical in understanding sex differences in addiction
associated behaviors reported in rodents and humans. These
include greater MA seeking and reinstatement to MA use
following a period of withdrawal in female rodents (Roth
and Carroll, 2004; Reichel et al., 2012). In humans, there are
numerous sex differences in MA abuse; women begin using
at an earlier age than men, have a shorter duration from first
use to regular use, and are more dependent on and committed
to MA (Brecht et al., 2004; Dluzen and Liu, 2008; SAMHSA,
2010). Sex differences in MA-induced alterations in the HPA
axis may contribute to these sexually dimorphic abuse patterns.
Of particular interest is the role of gonadal steroid hormones
estrogen, progesterone, and testosterone in regulating these
effects. Extensive literature indicates that estrogens enhance,
whereas androgens suppress, glucocorticoid release via activation
of estrogen and androgen receptor subtypes (Zuloaga et al., 2008,
2011; Handa and Weiser, 2014). These same hormones regulate
behavioral effects of psychostimulants such as cocaine self-
administration, reinstatement, and conditioned place preference
(Cooper et al., 2013; Ramoa et al., 2013; Bobzean et al., 2014). A
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TABLE 1 | MA effects on glucocorticoids, HPA axis associated genes/proteins, and stress-associated behaviors.
Effects References
Glucocorticoids Adult Acute exposure ↑ levels (rodent, non-human
primate, and human)
Zuloaga et al., 2014;
Madden et al., 2005;
Harris et al., 2003
Adult repeated exposure Alterations in circadian rhythm
(rat)
Morimasa et al., 1987;
Li et al., 2013
Decreased basal levels during
withdrawal (human)
Developmental acute exposure ↑ levels (mouse and rat) Grace et al., 2008;
Acevedo et al., 2008
Developmental repeated exposure Neonatal exposure: No effects
or subtle ↑ following adult
stressor (rat)
Grace et al., 2012
Prenatal Exposure: No effect
on basal levels (rat) Elevated
stress induced levels in 2 year
olds (human)
Cabrera et al., 1993;
Kirlic et al., 2013
HPA axis associated genes/proteins CRF Adult exposure: ↑ in CEA and
NAC (rat)
Nawata et al., 2012;
Cadet et al., 2014
AVP Neonatal/Juvenile exposure:
Lasting decreases in
AVP-expressing cells in the PVN
(mouse)
Zuloaga et al., 2013;
Joca et al., 2014.
GR Adult exposure: ↓ in
hippocampus, hypothalamus,
and striatum (rat)
Lowy and Novotney,
1994
MR Adult exposure: ↓ in
hippocampus (rat)
Lowy, 1990
Stress-associated behaviors Anxiety-related Prenatal exposure: No effects
(rat) ↑ in 3–5 year olds (human)
Hruba et al., 2012;
LaGasse et al., 2012
Neonatal exposure: Subtle↑ or
↓ found in adulthood, depends
on timing and dose (rat)
Williams et al., 2003;
Hruba et al., 2012
No effects (mouse) Eastwood et al., 2012;
Adult exposure: ↑ during
withdrawal (rat, human)
Nawata et al., 2012;
London et al., 2004
Depressive-related Prenatal exposure: ↑ in 3–5
year olds (human)
LaGasse et al., 2012
Juvenile exposure: ↑ in
adulthood (mouse)
Joca et al., 2014
Adult exposure: ↑ during
withdrawal (rat, human)
Jang et al., 2013; Li
et al., 2013
more comprehensive understanding of the interactions between
psychostimulant abuse processes, stress hormones, and gonadal
steroid hormones will provide insight into the underlying causes
of addiction.
Conclusions and Potential Therapeutics
MA is a potent activator of the HPA axis during both
development and adulthood. Prolonged release in plasma
corticosterone may contribute to a variety of effects reported
after MA administration. In particular, the altered expression
of genes/proteins associated with the HPA axis including CRF,
AVP, and GR which have been reported in a variety of HPA
axis associated brain regions. These neural effects of MA
have been linked to both elevated anxiety/despair states as
well as increased stress-induced reinstatement to MA use. MA
addiction has proven incredibly difficult to treat, particularly in
terms of psychotherapeutic interventions (Carson and Taylor,
2014). Compounds that alleviate HPA axis dysfunction such as
metyrapone and drugs that interact with receptors for CRF, AVP,
and glucocorticoids offer alternative mechanisms of treatment.
At present, only metyrapone has been assessed in the context
of human MA use although pre-clinical studies on other HPA
axis-associated compounds are emerging and may yield clinical
trials. For these compounds, it is essential to consider sex-specific
effects since both MA abuse patterns and HPA axis activation
differ between the sexes.
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